📰 Including Stroke News
Including Stroke News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Including Stroke. Real-time updates on events, politics, business and more.
September 11, 2023
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of multiple posters highlighting real-world and clinical data at the 36th Annual...
May 16, 2023
? Clinical and Patient Experience Research Delivers Insights into Treatment for People Living with Schizophrenia or Bipolar I Disorder ? DUBLIN, May 16, 2023 /PRNewswire/ -- Alkermes
April 17, 2023
The Prescription Drug User Fee Act (PDUFA) target action date is May 10, 2023PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Development & Commercialization, Inc., (Otsuka) and Lundbeck Pharmaceuticals LLC (Lundbeck) announce the Joint Meeting of the Psychopharmacologic Drugs Advisory C...
December 2, 2022
Researchers highlight efficacy and safety data across three Phase 3 studies of brexpiprazole for agitation in Alzheimer’s dementiaAgitation is a highly prevalent clinical manifestation in Alzheimer’s dementia and one of the most complex and stressful aspects of care in patients affected by the disease. It is associa...
September 20, 2022
? Clinical, Epidemiology and Health Economics and Outcomes Research Shared at Key Psychiatry Conference ? DUBLIN, Sept. 20, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced
April 7, 2022
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today presented new research from its psychiatry portfolio at the 2022 Congress of the Schizophrenia International...
April 7, 2022
- Detailed Results Presented From ENLIGHTEN-Early Phase 3b Study of LYBALVI in Patients Early in Illness - DUBLIN, April 7, 2022 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today presented
January 18, 2022
More ER visits for atrial fibrillation were found on days such as New Year’s, Christmas, and Super Bowl Sunday.
October 29, 2021
/PRNewswire/ -- AbbVie (NYSE: ABBV) today announced top-line results from two Phase 3 clinical trials, Study 3111-301-001 and Study 3111-302-001, evaluating...